|  | 
|  | 
|  | 
|  | 
|  | 
|  | 
| Drug Highest PhaseApproved | 
| First Approval Ctry. / Loc.United States | 
| First Approval Date17 Dec 1999 | 
|  | 
| Mechanism5-HT receptor modulators [+2]  | 
|  | 
|  | 
| Active Indication- | 
| Inactive Indication- | 
| Drug Highest PhasePhase 1 | 
| First Approval Ctry. / Loc.- | 
| First Approval Date- | 
 / Not yet recruitingPhase 2 A Phase-2, Double-Blind, Randomized, Placebo-controlled, Crossover Dose-Finding, Laboratory-based Study to Evaluate Effects on Sleep and Safety of RE03 in PTSD Patients With Sleep Disturbances
Post-traumatic stress disorder (PTSD) affects many people who have experienced traumatic events. A common issue with PTSD is severe sleep disturbances, such as nightmares. Current treatments often do not provide sufficient relief, especially for sleep problems. This study aims to determine whether dexmedetomidine - a medication already used in intensive care - can improve sleep quality in PTSD patients.
Double-blind, Randomized, Dose-response Study of RE02 in Healthy Subjects
The goal of this clinical trial is to compare corresponding inter- and intraindividual pharmacokinetic and pharmacodynamic profiles including assessments of safety & tolerability of three different doses against a placebo control.
Single-blind, Randomized, Two-arm, Dose-response Study of DMT and Harmine in Healthy Subjects
The goal of this clinical trial is to compare corresponding inter- and intraindividual pharmacokinetic and pharmacodynamic profiles including assessments of safety & tolerability.
100 Clinical Results associated with Reconnect Labs
0  Patents (Medical) associated with Reconnect Labs
100 Deals associated with Reconnect Labs
100 Translational Medicine associated with Reconnect Labs